Author Description

This volume presents the latest thinking on the use of Bacillus Calmette-Guérin (BCG) as a treatment for carcinoma of the urinary bladder. It examines the mechanisms by which the vaccine exerts its antitumor effects, and covers preferred treatment schedules, appropriate strains and optimal doses, exact placement of non-specific active immunotherapy, and risk-to-benefit analyses for the use of BCG therapy. Also, it discusses development of animal tumor systems and research on antitumor activity and mechanisms of action in humans with residual tumors or carcinoma in situ.